in vivo News and Research

RSS

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Geron Corporation today announced several presentations at the American Association for Cancer Research Special Conference on The Role of Telomeres and Telomerase in Cancer Research held in Fort Worth, TX between February 27th and March 1st.

3 Mar 2010

Simvastatin impairs ability of macrophages to kill pathogens, and enhances cytokine production

Simvastatin might help us control our cholesterol, but when it comes to infection, it's an entirely different story says a new research study published in the Journal of Leukocyte Biology. In the research report, scientists from Italy show that simvastatin delivers a one-two punch to the immune system. First it impairs the ability of specialized immune cells, called macrophages, to kill pathogens. Then, it enhances production of molecules, called cytokines, which trigger and sustain inflammation.

2 Mar 2010

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

BioSante Pharmaceuticals, Inc. today announced the receipt of two US patents directed to its 2A/Furin technology for expressing proteins. The first issued US patent, US Pat. No., 7,632,059, covers methods for manufacturing recombinant antibodies.

2 Mar 2010

Stryker Interventional Spine announces the U.S. launch of VertaPlex HV bone cement for VCFs

Stryker Interventional Spine today announced the U.S. launch of VertaPlex® HV. VertaPlex HV is a high viscosity bone cement for use in treating vertebral compression fractures.

From Stryker 2 Mar 2010

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

SIMPLE Antibody(TM) Platform Delivers Unprecedented Choice of Ultra-Potent Functional Antibody Leads Against Challenging Soluble and Cell Surface Targets. - ARGX-109, a Fully Human mAb Targeting Autoimmune, Inflammation and Oncology Indications, Enters Preclinical Development in Less Than 12 Months From Start of Discovery.

1 Mar 2010

Researchers find gene regulator that plays key role in DS-AMKL

Between 5 and 10 percent of babies with Down syndrome develop a transient form of leukemia that usually resolves on its own. However, for reasons that haven't been clear, 20 to 30 percent of these babies progress to a more serious leukemia known as Down syndrome acute megakaryoblastic leukemia (DS-AMKL), which affects the blood progenitor cells that form red blood cells and platelets.

1 Mar 2010

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

Absorption Systems, a leader in testing drugs for ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity), has joined the Society of Toxicology, the premier global professional association of toxicologists, as an SOT Affiliate. The firm, a contract research organization, has more than a decade of experience assisting pharmaceutical and biotechnology companies in determining which compounds in development should be advanced into clinical testing.

27 Feb 2010

BCRI study evaluates the effect of high-doses of vitamin C on inhibition of new blood vessel growth

Bio-Communications Research Institute's recent research study has found that high levels of vitamin C (ascorbate) inhibit the formation of new blood vessel growth to tumors.

27 Feb 2010

Fate Therapeutics named to Technology Review's 2010 TR50 most innovative companies in the world list

Fate Therapeutics, Inc. announced today that the Company was named as one of Technology Review's 2010 TR50, the publication's first annual list of the 50 most innovative companies in the world. The 2010 TR50 companies span the fields of energy, computing, the Web, biomedicine, and materials and have been evaluated based on business model, strategies for deploying and scaling up its technologies and the likelihood of success. Each company in the 2010 TR50 has excelled not only at inventing technology but also at using it to transform how we live and work.

26 Feb 2010

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.

25 Feb 2010

Caliper Life Sciences files patent infringement lawsuit against Carestream Health

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, and its wholly owned subsidiary Xenogen Corporation, today announced the filing of a patent infringement lawsuit in the U.S. District Court for the Eastern District of Texas.

25 Feb 2010

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

HIV/AIDS remains one of the world's most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis.

25 Feb 2010

Biochemical link between misery and death discovered

In ongoing work to identify how genes interact with social environments to impact human health, UCLA researchers have discovered what they describe as a biochemical link between misery and death. In addition, they found a specific genetic variation in some individuals that seems to disconnect that link, rendering them more biologically resilient in the face of adversity.

25 Feb 2010

Findings suggest bitter melon extract may help in preventing breast cancer

Bitter melon extract, a common dietary supplement, exerts a significant effect against breast cancer cell growth and may eventually become a chemopreventive agent against this form of cancer, according to results of a recent study.

23 Feb 2010

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

PsychoGenics Inc. today announced the establishment of an exclusive alliance with Dr. Jan Kehr, an internationally recognized expert in experimental neuropharmacology, to provide specialized microdialysis services to complement PsychoGenics’ in vivo testing capabilities.

19 Feb 2010

The Methodist Hospital Research Institute awarded $11.5M NIH grant for research into methods of targeting cancer stem cells

The Methodist Hospital Research Institute was awarded an $11.5 million Center Grant by the National Institutes for Health (NIH) today to study the best way to attack deadly cancer stem cells to enhance treatments for breast cancer. Other members of the team include Baylor College of Medicine and the University of Texas Health Science Center at Houston.

19 Feb 2010

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

Celator Pharmaceuticals today announced that the National Cancer Institute's (NCI) Nanotechnology Characterization Laboratory (NCL), operated by SAIC-Frederick (Frederick, Maryland), has agreed to conduct characterization studies to advance the development of the company's nanoparticle drug formulation technology.

18 Feb 2010

PositiveID acquires intellectual property rights and assets of Easy Check Medical Diagnostics

PositiveID Corporation announced today that it has acquired intellectual property rights and assets of Easy Check Medical Diagnostics, LLC, to expand its portfolio of non-invasive glucose-level testing products and diabetes management tools under development. Easy Check has two primary products under development: the Easy Check breath glucose detection system and the iGlucose™ wireless communication device.

17 Feb 2010

Directing gold nanoparticles into nucleus can kill cancer cells

Taking gold nanoparticles to the cancer cell and hitting them with a laser has been shown to be a promising tool in fighting cancer, but what about cancers that occur in places where a laser light can't reach? Scientists at the Georgia Institute of Technology have shown that by directing gold nanoparticles into the nuclei of cancer cells, they can not only prevent them from multiplying, but can kill them where they lurk. The research appeared as a communication in the February 10 edition of the Journal of the American Chemical Society.

17 Feb 2010

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

CalciMedica today announced that the US Patent and Trademark Office has issued to CalciMedica US Patent No. 7,645,588, a composition patent involving STIM1, a key component of the calcium release-activated calcium (CRAC) channel. The patent, entitled "Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use," has a priority date of March 4, 2003 and was issued on January 12, 2010.

17 Feb 2010

in vivo News and Research

Geron highlights telomerase inhibitor's activity against cancer stem cells at AACR Special Conference

Simvastatin impairs ability of macrophages to kill pathogens, and enhances cytokine production

BioSante Pharmaceuticals announces receipt of two US patents directed to 2A/Furin technology

Stryker Interventional Spine announces the U.S. launch of VertaPlex HV bone cement for VCFs

arGEN-X SIMPLE Antibody platform delivers multiple, diverse, ultra-potent functional antibodies

Researchers find gene regulator that plays key role in DS-AMKL

ADMET tester Absorption Systems joins Society of Toxicology as Affiliate

BCRI study evaluates the effect of high-doses of vitamin C on inhibition of new blood vessel growth

Fate Therapeutics named to Technology Review's 2010 TR50 most innovative companies in the world list

Regulus Therapeutics, GSK announce new collaboration on microRNA therapeutics targeting microRNA-122

Caliper Life Sciences files patent infringement lawsuit against Carestream Health

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

Biochemical link between misery and death discovered

Findings suggest bitter melon extract may help in preventing breast cancer

PsychoGenics announces alliance with experimental neuropharmacology expert for specialized microdialysis services

The Methodist Hospital Research Institute awarded $11.5M NIH grant for research into methods of targeting cancer stem cells

NCI's NCL to conduct characterization studies of Celator Pharmaceuticals' HDPN formulation

PositiveID acquires intellectual property rights and assets of Easy Check Medical Diagnostics

Directing gold nanoparticles into nucleus can kill cancer cells

CalciMedica granted U.S. composition patent concerning key component of CRAC channel

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News